Mobile

AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)

Update Il y a 4 ans
Reference: EUCTR2010-018585-23

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

 Compare the progression-free survival (PFS) of treatment-naïve patients with mRCC receiving AG-013736 vs sorafenib.  Estimate the progression-free survival (PFS) of previously-treated Asian patients with mRCC receiving AG-013736 vs sorafenib.

Inclusion criteria

  • metastatic renal cell cancer

Links